ACRO BIOMEDICAL CO., LTD.
ACRO BIOMEDICAL CO., LTD.
No insider data available
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Accounts Receivable Net Current | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | |||||
Assets Current | |||||||||||||||||
Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |||||
Prepaid Expense Current | 0 | 0 | - | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Security Deposit | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Deposits Assets Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | |||||
Operating Lease Right Of Use Asset | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Accounts Payable And Accrued Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Deferred Revenue Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities Current | |||||||||||||||||
Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Other Liabilities Current | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | |||||
Operating Lease Liability Current | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Operating Lease Liability Noncurrent | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - | - | |||||
Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | - | |||||
Stockholders Equity | |||||||||||||||||
Additional Paid In Capital | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | 32 | |||||
Stockholders Equity | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | |||||
Retained Earnings Accumulated Deficit | -33 | -33 | -33 | -33 | -33 | -33 | -33 | -33 | -33 | -33 | -33 | -31 | |||||
Deferred Compensation Equity | - | - | - | - | - | - | - | - | - | 0 | 0 | -1 | |||||
Liabilities And Stockholders Equity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |||||
Preferred Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Preferred Stock Shares Authorized | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | |||||
Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Common Stock Par Or Stated Value Per Share | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | |||||
Common Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |||||
Common Stock Shares Issued | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | |||||
Shares Outstanding | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.00% | 0.00% | 0.00% | - | - | - | - | - | - | - | - | - |
| 2025 | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3071.43% | 3071.43% | 0.00% | 17.12% | 17.12% |
| 2024 | 0.00% | 0.00% | 0.00% | - | - | - | 0.00% | 0.00% | 0.00% | - | - | - |
| 2023 | -34.78% | 30.43% | 30.43% | 30.43% | 30.43% | 30.43% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 2022 | - | - | - | - | - | - | - | - | - | 0.00% | 30.43% | 30.43% |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 50+ calculated metrics
Subscribe to unlock 17+ years of data and 50+ calculated metrics
Performance and Valuation Metrics
Metrics | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 0.01 | 0.04 | 0.01 | 0.11 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.01 | 0.05 | 2.64 | |||||
| Quick Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 2.59 | |||||
| Working Capital | -427.24K | -386.96K | -432.62K | -331.17K | -324.23K | -321.87K | -316.60K | -307.10K | -297.63K | -286.95K | -246.14K | 326.67K | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | -1.01 | -1.04 | -1.01 | -1.17 | -1.08 | -1.11 | -1.14 | -1.16 | -1.19 | -1.23 | -1.08 | 0.59 | |||||
| Debt Ratio | 111.31 | 28.45 | 101.07 | 6.96 | 13.07 | 10.23 | 8.38 | 7.10 | 6.26 | 5.40 | 13.59 | 0.37 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.09 | 0.60 | |||||
| Days Sales Outstanding TTM | - | - | - | - | - | - | - | - | - | - | - | 404.03 | |||||
| Receivables Turnover TTM | - | - | - | - | - | - | - | - | - | - | - | 0.90 | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.03 | -0.08 | -0.15 | -0.21 | -0.25 | |||||
| Free Cash Flow Per Share TTM | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Margin Metrics | |||||||||||||||||
| Operating Profit Margin TTM | - | - | - | - | - | - | - | - | - | - | -3,533.57% | -4,206.38% | |||||
| Net Profit Margin TTM | - | - | - | - | - | - | - | - | - | - | -3,534.45% | -4,207.18% | |||||
Growth Metrics | |||||||||||||||||
| Net Revenue Growth (1Y) | - | - | - | - | - | - | -100.00% | -100.00% | -100.00% | -100.00% | -59.84% | -59.84% | |||||
| Net Income Growth (1Y) | 225.59% | 139.13% | 209.53% | -97.13% | -99.14% | -99.52% | -99.61% | -89.24% | -69.81% | -44.51% | -19.42% | 2.55% | |||||
| EPS Growth (1Y) | 225.59% | 139.13% | 209.53% | -97.13% | -99.14% | -99.52% | -99.61% | -89.24% | -69.81% | -44.51% | -19.42% | 2.55% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -11.60 | -13.18 | -0.27 | -0.90 | -1.02 | -0.99 | -0.84 | -3.87 | -1.31 | -0.72 | -7.08 | -4.56 | |||||
| P/B TTM | -3.65 | -3.44 | -0.10 | -0.13 | -0.14 | -0.14 | -0.15 | -22.81 | -23.58 | -24.53 | -375.87 | 203.29 | |||||
| P/S TTM | - | - | - | - | - | - | - | - | - | - | 250.18 | 191.80 | |||||
| Market Cap | 1.56M | 1.33M | 42.03K | 42.03K | 42.03K | 42.03K | 42.03K | 6.30M | 6.30M | 6.30M | 90.06M | 69.05M | |||||
| Enterprise Value | 1.56M | 1.33M | 37.71K | 42.00K | 41.78K | 41.55K | 41.33K | 6.30M | 6.30M | 6.30M | 90.06M | 69.05M | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | -223.59K | -196.30K | -181.44K | -133.37K | -45.71K | -36.69K | -38.79K | -31.97K | -23.39K | -15.45K | -13.40K | -67.15K | |||||
| Net Debt | -3.87K | 502.00 | -4.32K | -26.00 | -251.00 | -476.00 | -701.00 | -926.00 | -151.00 | -376.00 | -3.27K | -2.68K | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
ACRO BIOMEDICAL CO., LTD. (ACBM) — SEC Financial Statements & Analysis
ACRO BIOMEDICAL CO., LTD. (ACBM) is a services-amusement & recreation services company, incorporated in NV. ACRO BIOMEDICAL CO., LTD. trades on ACBM: OTC as: ACBM. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), ACRO BIOMEDICAL CO., LTD. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of -1.01x, a Price-to-Sales (P/S) ratio of 250.18x (TTM), a Price-to-Book (P/B) ratio of -3.65 (TTM), at a market cap of $1.56M. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- -100.00%
- Debt To Equity
- -1.01x
- P/S TTM
- 250.18x
- P/B TTM
- -3.65
- Market Cap
- $1.56M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is ACRO BIOMEDICAL CO., LTD. in?
ACRO BIOMEDICAL CO., LTD. (ACBM) operates in the Services-Amusement & Recreation Services industry.
What is ACBM's market cap?
ACRO BIOMEDICAL CO., LTD. (ACBM) has a market capitalization of $1.56M as of 2026-03-31.
What exchange does ACBM trade on?
ACRO BIOMEDICAL CO., LTD. (ACBM) trades on the ACBM: OTC.
Where is ACRO BIOMEDICAL CO., LTD. incorporated?
ACRO BIOMEDICAL CO., LTD. is incorporated in NV.